Spyre Therapeutics, Inc. — Director's Dealing 2021

Jun 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2021-06-08

Reporting Person: Lawton Alison Frances (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-08	Director Stock Option (right to buy)	$6.80	A	40000	Acquired	2031-06-07	Common Stock (40000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.